Please login to the form below
subcutaneous injection
This page shows the latest subcutaneous injection news and features for those working in and with pharma, biotech and healthcare.
AbbVie announces positive results from head-to-head study of Skyrizi in Crohn's disease
The late-stage SEQUENCE study has been evaluating the drugs, both given as a subcutaneous injection every eight weeks after a lead-in period of intravenous infusions, in patients with moderately
Latest news
-
BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody
The antibody is currently being studied as a subcutaneous injection in a global phase 3 trial in patients with IgG4-related disease (IgG4-RD), which currently has no approved treatments, and
-
NHS England to offer world-first seven-minute cancer treatment injection
Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%. ... However, approximately 3, 600 patients are set to receive a seven-minute subcutaneous injection of Tencentriq, reducing treatment time by up to 75% and easing
-
Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer
Talvey, which is administered as a weekly or bi-weekly subcutaneous injection after an initial step-up phase, is a bispecific antibody that binds to CD3 on the surface of T
-
Janssen receives positive CHMP opinion for Talvey in multiple myeloma
Talvey, which is administered by subcutaneous injection, works by binding to CD3, on T-cells, and GPRC5D, which is a novel target on multiple myeloma cells.
-
Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial
The Ocrevus subcutaneous injection was shown to be non-inferior to the IV, as measured by pharmacokinetics (levels in the blood) over 12 weeks. ... The subcutaneous injection was also comparable in controlling MRI lesion activity in the brain over 12
More from news
Approximately 2 fully matching, plus 108 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
It’s given as a subcutaneous injection that takes less than a minute to deliver every two weeks, around 75% fewer injections than other products for HAE prevention. ... Injection volumes are lower, it can be taken weekly as well as monthly and can be
-
Implementing eHealth innovation
Growth hormone treatment (GHT) is only available on prescription and is given as a subcutaneous injection (directly under the skin). ... complete, partial, missed) of each injection, and uploads this data wirelessly from the patients’ homes to the
-
Deal Watch November 2016
Arsia has a proprietary viscosity reducing technology and know-how to enable the development of high concentration formulations of biologics that can be administered by subcutaneous injection rather than intravenously. ... Invossa, cell-mediated gene
-
Deal Watch July 2016
cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... The presentation is subcutaneous injection in both indications, leaving
-
Oral biologics delivery still elusive
At the moment, biologics are generally delivered by intravenous or subcutaneous injection, which is effective but not desirable for patients, particularly for chronic conditions.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
AP Pharma overhauls senior management team
drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
